Gastroenteropancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors [Phase 1, Phase 2]
Perspective Therapeutics is recruiting for a Phase 1/Phase 2 study of targeted alpha-particle therapy for advanced SSTR2-positive neuroendoc…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. [Phase 3]
This entry notes an open-label Phase 3 clinical trial evaluating Lutetium-177 Lu oxodotreotide for advanced gastroenteropancreatic neuroendo…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET [Phase 3]
A Phase 3 trial is evaluating the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1-2 advanced gastroenteropancreatic neur…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial [Phase 2]
This clinical trial update describes a Phase 2 study (NET RETREAT) evaluating retreatment with 177Lu-DOTATATE peptide receptor radionuclide …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. [Phase 1]
This is a Phase 1 clinical trial update for RayzeBio's RYZ401 in subjects with solid tumors expressing somatostatin receptors; the study is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]
A phase 1/2 trial evaluating the combination of cabozantinib and lanreotide for gastroenteropancreatic neuroendocrine tumors is currently re…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating lutetium Lu-177 dotatate (Lutathera) in combination with olaparib for inoperable gastroenteropancre…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy [Phase 3]
Phase 3 trial update for RYZ101 versus standard of care in patients with inoperable, well-differentiated SSTR-positive gastroenteropancreati…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
A clinical trial entry indicates that a study evaluating peptide receptor radionuclide therapy for neuroendocrine tumors is currently recrui…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors
This entry reports the completion of a clinical trial cohort studying well-differentiated grade 3 neuroendocrine tumors of the digestive tra…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
This update describes an ongoing clinical trial (NCT06356467) evaluating how tumor characteristics and patient-related factors influence res…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases [Phase 2]
Phase 2 trial evaluating adjuvant 177Lu-DOTATATE versus best supportive care after surgical resection of neuroendocrine liver metastases; th…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital
The Strasbourg University Hospital is conducting a clinical trial to assess nutritional status in adult patients with gastroenteropancreatic…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors [Phase 2]
CVM-1118 is being studied in a Phase 2 trial for advanced neuroendocrine tumors. The study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Neuroendocrine Tumors - Patient Reported Outcomes
Clinical trial update on patient-reported outcomes for neuroendocrine tumors in the NCT05064150 study sponsored by the University of Iowa; t…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors [Phase 4]
This study evaluates whether surgical debulking prior to peptide receptor radionuclide therapy improves outcomes in well-differentiated gast…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) [Phase 1]
Phase 1 study evaluating Debio 4126 in participants with acromegaly or functioning gastroenteropancreatic neuroendocrine tumors has been ter…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy and safety of octreotide subcutaneous depot in patients with gastroenteropancreatic neur…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers [Phase 2]
A national platform coordinating five Phase II academic trials at Lyon to assess the safety and efficacy of the domvanalimab + zimberelimab …
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy for metastatic, poorly differentiated Grade 3 neuroendocrine carcinoma of gastroenteropancr…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort [NA]
A prospective interventional national cohort study in France to characterize gastroenteropancreatic neuroendocrine tumors treated with targe…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) [Phase 3]
Phase 3 trial PReCedeNT comparing PRRT alone versus PRRT with chemotherapy for gastroenteropancreatic neuroendocrine tumors is currently rec…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE [Phase 3]
Phase 3 clinical trial comparing Lutetium-177Lu-Edotreotide to best standard of care in well-differentiated aggressive grade-2/grade-3 gastr…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery [Phase 1]
Phase 1 trial evaluating PRRT in metastatic gastroenteropancreatic neuroendocrine tumors that are SSTR-positive and candidates for cytoreduc…
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs [Phase 3]
A Phase 3 clinical trial compares Lutetium-177Lu oxodotreotide with Octreotide LAR in patients with gastroenteropancreatic neuroendocrine tu…